{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:59:33Z","timestamp":1789786773232,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s13300-011-0004-1","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T06:12:26Z","timestamp":1309759946000},"page":"133-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes"],"prefix":"10.1007","volume":"2","author":[{"given":"Timothy Colin","family":"Hardman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon William","family":"Dubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"4_CR1","unstructured":"American Diabetes Association website. Available at: http:\/\/www.diabetes.org\/diabetes-basics\/diabetes-statistics\/?utm_source=www&utm_medium=DropDownDB&utm_content=Statistics&utm_campaign=CON. Accessed 14 June 2011."},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0106-75","volume":"12","author":"S. Smyth","year":"2006","unstructured":"Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2006;12:75\u201380.","journal-title":"Nat Med"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2337\/diacare.27.2.407","volume":"27","author":"D.G. Manuel","year":"2004","unstructured":"Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996\u20131997. Diabetes Care. 2004;27:407\u2013414.","journal-title":"Diabetes Care"},{"issue":"Suppl.","key":"4_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2337\/diacare.26.2007.S28","volume":"26","author":"American Diabetes Association.","year":"2003","unstructured":"American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26(Suppl.):S 28\u201332.","journal-title":"Diabetes Care"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u2013865.","journal-title":"Lancet"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes ControlComplications Trial Research Group.","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u2013986.","journal-title":"N Engl J Med"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00125-006-0316-2","volume":"49","author":"D.M. Nathan","year":"2006","unstructured":"Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711\u20131721.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR8","first-page":"4","volume":"13","author":"AACE Diabetes Mellitus Clinical Practice Guidelines Task Force.","year":"2007","unstructured":"AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. Endocr Pract. 2007;13(Suppl. 1):4\u201368.","journal-title":"Endocr Pract"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2337\/dc07-S004","volume":"30","author":"American Diabetes Association.","year":"2007","unstructured":"American Diabetes Association. Standards of Medical Care in Diabetes 2007. Diabetes Care. 2007;30:S4\u2013S41.","journal-title":"Diabetes Care"},{"key":"4_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y. Kanai","year":"1994","unstructured":"Kanai Y, Lee W-S, You G Y, Brown D, Hediger MA. The human kidney low affinity Na+ \/ glucose cotransporter SGLT2. J Clin Invest. 1994;93:397\u2013404.","journal-title":"J Clin Invest"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ki.2009.87","volume":"75","author":"G.L. Bakris","year":"2009","unstructured":"Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272\u20131277.","journal-title":"Kidney Int"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"E.M. Wright","year":"2001","unstructured":"Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280:F10\u201318.","journal-title":"Am J Physiol Renal Physiol"},{"key":"4_CR13","first-page":"701","volume-title":"Pediatric Nephrology","author":"I. Zelikovic","year":"2004","unstructured":"Zelikovic I. Aminoaciduria and glycosuria. In: Avner ED, Harmon WE and Niaudet P, eds. Pediatric Nephrology. 5th edition. Philadelphia: Lippincott Williams & Wilkins: 2004;701\u2013728.","edition":"5th edition"},{"key":"4_CR14","first-page":"214","volume-title":"Brenner and Rector\u2019s The Kidney","author":"O.W. Moe","year":"2008","unstructured":"Moe OW, Wright SH and Palac\u00edn M. Renal handling of organic solutes. In: Brenner BM, ed. Brenner and Rector\u2019s The Kidney. 8th edition. Philadelphia: Saunders Elsevier: 2008;214\u2013247.","edition":"8th edition"},{"key":"4_CR15","first-page":"439","volume-title":"Membrane Transport and Metabolism. Proceedings of a Symposium held in Prague","author":"D. Miller","year":"1960","unstructured":"Miller D and Bihler I. The restrictions on possible mechanisms of intestinal transport of sugars. In: Kleinzeller A and Kotyk A, eds. Membrane Transport and Metabolism. Proceedings of a Symposium held in Prague. Prague: Czech Academy of Sciences & Academic Press: 1960;439\u201349."},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"L. Rossetti","year":"1987","unstructured":"Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037\u20131044.","journal-title":"J Clin Invest"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"R.R.L. Ehrenkranz","year":"2005","unstructured":"Ehrenkranz RRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31\u201338.","journal-title":"Diabetes Metab Res Rev"},{"key":"4_CR18","first-page":"3","volume-title":"Lectures on the Kidney","author":"H.W. Smith","year":"1943","unstructured":"Smith HW. The evolution of the kidney. In: Smith HW ed. Lectures on the Kidney. Kansas: University of Kansas Press: 1943;3."},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1152\/ajplegacy.1973.224.3.552","volume":"224","author":"H.D. Vick","year":"1973","unstructured":"Vick HD, Deidrich DF, Baumann K. Re-evaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol. 1973;224:552\u2013557.","journal-title":"Am J Physiol"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0304-4157(76)90003-4","volume":"457","author":"M. Silverman","year":"1976","unstructured":"Silverman M. Glucose transport in the kidney. Biochim Biophys Acta. 1976;457:303\u2013351.","journal-title":"Biochim Biophys Acta"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1113\/jphysiol.1978.sp012201","volume":"275","author":"J.H. Bishop","year":"1978","unstructured":"Bishop JH, Elegbe R, Green R, Thomas S. Effects of phlorizin on glucose, water and sodium handling by the rat kidney. J Physiol. 1978;275:467\u2013480.","journal-title":"J Physiol"},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/330379a0","volume":"330","author":"M.A. Hediger","year":"1987","unstructured":"Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter. Nature. 1987;330:379\u2013381.","journal-title":"Nature"},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"E.M. Wright","year":"2007","unstructured":"Wright EM, Hirayama BA and Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32\u201343.","journal-title":"J Intern Med"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","volume":"447","author":"E.M. Wright","year":"2004","unstructured":"Wright EM and Turk E. The sodium\/glucose cotransport family SLC5. Eur J Physiol. 2004;447:510\u2013518.","journal-title":"Eur J Physiol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1021\/jm990175n","volume":"42","author":"K. Tsujihara","year":"1999","unstructured":"Tsujihara K, Hongu M, Saito K, et al. Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4\u2032-dihydroxyphlorizin derivative substituted on the B ring. J Med Chem. 1999;42:5311\u20135324.","journal-title":"J Med Chem"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0014-2999(00)00016-9","volume":"391","author":"A. Oku","year":"2000","unstructured":"Oku A, Ueta K, Nawano M, et al. Antidiabetic effect of T-1095, an inhibitor of Na+-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391:183\u2013192.","journal-title":"Eur J Pharmacol"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1517\/13543770903337828","volume":"19","author":"W.N. Washburn","year":"2009","unstructured":"Washburn WN. Evolution of sodium glucose cotransporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Patents. 2009;19:1485\u20131499.","journal-title":"Expert Opin Ther Patents"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"E535","DOI":"10.1152\/ajpendo.2000.278.3.E535","volume":"278","author":"M. Nawano","year":"2000","unstructured":"Nawano M, Oku A, Ueta K, et al. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab. 2000;278:E535\u2013543.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.2337\/db05-1511","volume":"55","author":"Y. Fujimoto","year":"2006","unstructured":"Fujimoto Y, Torres TP, Donahue EP, Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006;55:2479\u20132490.","journal-title":"Diabetes"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1440-1681.2002.03671.x","volume":"29","author":"K. Nunoi","year":"2002","unstructured":"Nunoi K, Yasuda K, Adachi T, et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol. 2002;29:386\u2013390.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","volume":"132","author":"K. Arakawa","year":"2001","unstructured":"Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL\/KsJdb\/ db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578\u2013586.","journal-title":"Br J Pharmacol"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1016\/j.lfs.2004.09.038","volume":"76","author":"K. Ueta","year":"2005","unstructured":"Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sci. 2005;76:2655\u20132668.","journal-title":"Life Sci"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1021\/jm8013019","volume":"52","author":"W.N. Washburn","year":"2009","unstructured":"Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem. 2009;52:1785\u20131794.","journal-title":"J Med Chem"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.106.110296","volume":"320","author":"K. Katsuno","year":"2007","unstructured":"Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323\u2013330.","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1021\/jm200049r","volume":"54","author":"V. Mascitti","year":"2011","unstructured":"Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 Inhibitors. J Med Chem. 2011;54:2952\u20132960.","journal-title":"J Med Chem"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","volume":"13","author":"S. Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diab Ob Metab. 2011;13:357\u2013365.","journal-title":"Diab Ob Metab"},{"key":"4_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","volume":"13","author":"S. Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diab Ob Metab. 2011;13:47\u201354.","journal-title":"Diab Ob Metab"},{"issue":"Suppl.1","key":"4_CR38","first-page":"S348","volume":"53","author":"J.P.H. Wilding","year":"2010","unstructured":"Wilding JPH, Woo V, Pahor A, Sugg J, Langkilde A, Parikh S. Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia. 2010;53(Suppl. 1):S348.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR39","first-page":"S17","volume":"87","author":"C.M. Ng","year":"2010","unstructured":"Ng CM, Zhang L, List J, Pfister M. Mechanismbased disease model to describe the plasma\/urine glucose-time profiles in placebo-or dapagliflozin-treated normal and type 2 diabetes mellitus (T2DM) subjects. Clin Pharm Ther. 2010;87(Suppl. 1):S17\u2013S18.","journal-title":"Clin Pharm Ther"},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B. Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharm Ther. 2009;85:520\u2013526.","journal-title":"Clin Pharm Ther"},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B. Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharm Ther. 2009;85:513\u2013519.","journal-title":"Clin Pharm Ther"},{"issue":"Suppl.1","key":"4_CR42","first-page":"S15","volume":"85","author":"Y. Feng","year":"2009","unstructured":"Feng Y, Kasichayanula S, Leslie B, List J, Zhang L, Pfister M. Dapagliflozin mechanism of action in type 2 diabetes mellitus: characterization of biomarker response. Clin Pharm Ther. 2009;85(Suppl. 1):S15.","journal-title":"Clin Pharm Ther"},{"issue":"Suppl.1","key":"4_CR43","first-page":"S35","volume":"87","author":"D. Skee","year":"2010","unstructured":"Skee D, Shalayda K, Vandebosch A, Usiskin K, Tickel-Logan R, Devineni D. The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel. Clin Pharm Ther. 2010;87(Suppl. 1):S35.","journal-title":"Clin Pharm Ther"},{"issue":"Suppl.1","key":"4_CR44","first-page":"S349","volume":"53","author":"J. Rosenstock","year":"2010","unstructured":"Rosenstock J, Polidori D, Zhao Y, et al. Canagliflozin, an inhibitor of sodium glucose cotransporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin. Diabetologia. 2010;53(Suppl. 1):S349.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR45","first-page":"S349","volume":"53","author":"T. Sarich","year":"2010","unstructured":"Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, increases 24-hour urinary glucose excretion and reduces body weight in obese subjects over 2 weeks of treatment. Diabetologia. 2010;53(Suppl. 1):S349\u2013S350.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR46","first-page":"S350","volume":"53","author":"P.L. Rothenberg","year":"2010","unstructured":"Rothenberg PL, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes: Results of a phase 1b study. Diabetologia. 2010;53(Suppl. 1):S350\u2013S351.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR47","first-page":"S350","volume":"53","author":"D. Polidori","year":"2010","unstructured":"Polidori D, Sha S, Sarich T, Devineni D, Rothenberg PL. Canagliflozin lowers the renal threshold for glucose excretion in lean, obese and type 2 diabetic subjects. Diabetologia. 2010;53(Suppl. 1):S350.","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"4_CR48","first-page":"S81","volume":"89","author":"W. Zhang","year":"2011","unstructured":"Zhang W, Townsend R, Abeyratne A, Smulders R. Lack of pharmacokinetic interactions between ASP1941, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, and sitagliptin in healthy subjects. Clin Pharm Ther. 2011;89(Suppl. 1):S81\u2013S82.","journal-title":"Clin Pharm Ther"},{"issue":"Suppl.1","key":"4_CR49","first-page":"S82","volume":"89","author":"W. Zhang","year":"2011","unstructured":"Zhang W, Townsend R, Abeyratne A, Smulders R. Lack of pharmacokinetic interactions between ASP1941, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, and pioglitazone in healthy subjects. Clin Pharm Ther. 2011;89(Suppl. 1):S82.","journal-title":"Clin Pharm Ther"},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/0091270009351879","volume":"50","author":"E.K. Hussey","year":"2010","unstructured":"Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010;50:623\u2013635.","journal-title":"J Clin Pharmacol"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/0091270009352185","volume":"50","author":"E.K. Hussey","year":"2010","unstructured":"Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010;50:636\u2013646.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl.1A","key":"4_CR52","first-page":"582P","volume":"58","author":"E.K. Hussey","year":"2009","unstructured":"Hussey EK, Kapur A, O\u2019Connor-Semmes RL, Tao W, Poo JL, Dobbins RL. Safety, pharmacokinetics and pharmacodynamics of Remogliflozin etabonate (SGLT2 Inhibitor) and metformin when co-administered in type 2 diabetes mellitus (T2DM) patients. Diabetes. 2009;58(Suppl. 1A):582P.","journal-title":"Diabetes"},{"issue":"Suppl.1A","key":"4_CR53","first-page":"509P","volume":"58","author":"A. Kapur","year":"2009","unstructured":"Kapur A, O\u2019Connor-Semmes RL, Hussey EK, et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2009;58(Suppl. 1A):509P.","journal-title":"Diabetes"},{"issue":"Suppl.1A","key":"4_CR54","first-page":"573P","volume":"58","author":"R.L. Dobbins","year":"2009","unstructured":"Dobbins RL, Kapur A, Kapitza C, O\u2019Connor-Semmes RL, Tao W, Hussey EK. Remogliflozin etabonate, a selective inhibitor of the sodiumglucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes. 2009;58(Suppl. 1A):573P.","journal-title":"Diabetes"},{"key":"4_CR55","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"E.C. Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition \u2014 a novel strategy for diabetes treatment. Nat Rev Drug Disc. 2010;9:551\u2013559.","journal-title":"Nat Rev Drug Disc"},{"key":"4_CR56","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1002\/dmrr.517","volume":"20","author":"R. Landgraf","year":"2004","unstructured":"Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev. 2004;20:S9\u2013S12.","journal-title":"Diabetes Metab Res Rev"},{"key":"4_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1517\/14656566.2011.542150","volume":"12","author":"M. Shomali","year":"2011","unstructured":"Shomali M. Add-on therapies to metformin for type 2 diabetes. Expert Opin Pharmacother. 2011;12:47\u201362.","journal-title":"Expert Opin Pharmacother"},{"key":"4_CR58","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"J.F. List","year":"2009","unstructured":"List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650\u2013657.","journal-title":"Diabetes Care"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W. Meng","year":"2008","unstructured":"Meng W, Elsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51:1145\u20131149.","journal-title":"J Med Chem"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"J.P. Wilding","year":"2009","unstructured":"Wilding JP, Norwood P, T\u2019joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656\u20131662.","journal-title":"Diabetes Care"},{"key":"4_CR61","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"C.J. Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223\u20132233.","journal-title":"Lancet"},{"key":"4_CR62","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","volume":"23","author":"S.E. Geerlings","year":"2000","unstructured":"Geerlings SE, Stolk RP, Camps, Netten PM, Collet TJ, Hoepelman AIM, on behalf of the Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23:1737\u20131741.","journal-title":"Diabetes Care"},{"key":"4_CR63","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"M.J. Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee H-Y, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic (beta)-cell function. Diabetes. 2011;60:890\u2013898.","journal-title":"Diabetes"},{"key":"4_CR64","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/00002018-200730120-00005","volume":"30","author":"K. Hermansen","year":"2007","unstructured":"Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30:1127\u20131142.","journal-title":"Drug Saf"},{"key":"4_CR65","doi-asserted-by":"crossref","unstructured":"Goudswaard AN, Furlong NJ, Rutten GE, Valk GD, Stolk RP, Rutten GEHM. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004:CD003418.","DOI":"10.1002\/14651858.CD003418.pub2"},{"key":"4_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/diacare.27.1.256","volume":"27","author":"R.W. Nesto","year":"2004","unstructured":"Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256\u2013263.","journal-title":"Diabetes Care"},{"key":"4_CR67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/157340106775471958","volume":"2","author":"M. Ryan","year":"2006","unstructured":"Ryan M, Livingstone MBE, Ritz P. Insulin treatment and weight gain in type 2 diabetes: is our knowledge complete? Current Nutrition and Food Science. 2006;2:51\u201358.","journal-title":"Current Nutrition and Food Science"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-011-0004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-011-0004-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s13300-011-0004-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-011-0004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:47:33Z","timestamp":1724413653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-011-0004-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s13300-011-0004-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]},"assertion":[{"value":"7 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2011","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}